# AZD2115 Single Ascending Dose Study

> **NCT01283984** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 96 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease
- Lung Disease Causing Persistent Narrowing of the Airways

## Interventions

- **DRUG:** AZD2115
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01283984
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2011-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01283984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01283984, "AZD2115 Single Ascending Dose Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01283984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*